Physician profile
Benjamin John Thomas
NPI 1427290360
$62,238.43
in general payments reported to CMS, 2019-2025
24 companies · $4,074 in 2025
The $4,074 reported for 2025 was more than what 93% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,054 · 2020: $4,410 · 2021: $6,635 · 2022: $14K · 2023: $6,904 · 2024: $25K · 2025: $4,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Travel and Lodging: $2,242 · Food and Beverage: $2,234 · Acquisitions: $1,663 · Consulting Fee: $1,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,955.75 |
| Travel and Lodging | $2,241.72 |
| Food and Beverage | $2,233.86 |
| Acquisitions | $1,662.90 |
| Consulting Fee | $1,600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $29,093.37 | 2019-2025 | Eylea Hd, Eylea |
| Allergan, INC. | $14,789.49 | 2019-2022 | |
| Abbvie INC. | $11,916.81 | 2022-2025 | Ozurdex |
| US Retina LLC | $2,792.40 | 2019-2023 | |
| Alcon Vision LLC | $1,015.38 | 2020-2025 | Constellation, Unity |
| Genentech USA, INC. | $740.87 | 2019-2025 | Vabysmo |
| Novartis Pharmaceuticals Corporation | $410.07 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $280.11 | 2022-2025 | Syfovre |
| Bausch & Lomb Americas INC. | $224.68 | 2022-2024 | Xipere |
| Coherus Oncology, INC. | $219.73 | 2022-2024 | |
| Astellas Pharma US INC | $192.01 | 2023-2025 | Izervay |
| Alimera Sciences, INC. | $156.33 | 2019-2024 | Yutiq, Iluvien |
| Biogen, INC. | $135.74 | 2022-2024 | Byooviz |
| Mallinckrodt Hospital Products INC. | $74.87 | 2021-2023 | Acthar |
| Notal Vision, INC. | $46.01 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oculus Surgical INC. | $44.02 | 2022 | |
| Harrow Eye, LLC | $36.42 | 2024-2025 | Iheezo |
| Eyepoint US, INC. | $26.23 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $24.11 | 2024 | Purified Cortrophin Gel |
| Sandoz INC. | $19.78 | 2024 | Cimerli |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$13,742.66 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.